Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/19/2018
Start Date:January 2016
End Date:December 2019
Contact:Kerry M. Barnhart, Ph.D.
Email:kerry.barnhart@cerrx.com

Use our guide to learn which trials are right for you!

Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

This study addresses the hypothesis that intermittent treatment with fenretinide intravenous
emulsion will induce objective responses in patients with relapsed or refractory Peripheral
T-cell Lymphoma (PTCL) who have failed at least one prior systemic therapy and will result in
acceptable toxicities.

This is an open-label, multicenter, single arm efficacy and safety study in patients with
relapsed or refractory peripheral T-cell lymphoma, who have failed at least one prior system
therapy.

Approximately 140 patients will be enrolled. Patients will be treated with fenretinide
(4-HPR) intravenous emulsion administered as a continuous intravenous infusion for 5 days,
once every 3 weeks until there is disease progression or unmanageable treatment-related
toxicities.

The primary study endpoint is objective response rate (ORR). Responses will be categorized
using criteria established by the International Harmonization Project on Lymphoma. Safety
will be evaluated during the study and for 30 days after the last administration of study
drug. Adverse events and laboratory studies will be graded according to NCI-CTCAE v. 4.03.

Inclusion Criteria:

- Adult patients > 18 years with histologically or cytologically confirmed Peripheral
T-cell lymphoma (PTCL)

- Diseases refractory/relapsed after one or more systemic cytotoxic therapies; patients
must have fully recovered from the acute toxic effects of all prior chemotherapy,
immunotherapy, or radiotherapy prior to entering this study.

- Patients with an ECOG performance status of 0, 1, or 2, and estimated survival of > 12
weeks.

- Patients with at least ONE of the following sites of measurable disease according to
International Workshop Criteria87: A) Measurable tumor on MRI or CT scan. Measurable
is defined as at least one lesion 20 mm in at least one dimension; for spiral CT,
measurable is defined as 10 mm in at least one dimension. For patients with persistent
disease, a biopsy of bone marrow, or bone, or a soft tissue site, must have
demonstrated viable tumor. If lesion was radiated, biopsy must have been done at least
4 weeks after radiation completed. B) Bone marrow with tumor cells seen on routine
morphology (not by NSE staining only) of bilateral aspirate and/or biopsy on one bone
marrow sample, except for patient who tested positive subsequent to their last
treatment regimen or patients who had a negative marrow within three months of study
entry.

Exclusion Criteria:

- Unable to give written informed consent

- Patients who have received chemotherapy within 3 weeks of first fenretinide treatment,
or who have received investigational drugs within 6 weeks of first fenretinide
treatment. Patients must have otherwise recovered from toxicities of prior therapy.

- Patient is not eligible if radiation was given to the only site of measurable disease
unless there has been subsequent disease progression at that site, or a biopsy of that
site showed viable tumor at least 4 weeks after radiation was completed. Patients must
not have received small field (focal) radiation for a minimum of 2 weeks prior to
study entry. A minimum of 6 weeks is required following prior large field radiation
therapy (i.e. TBI, craniospinal therapy, whole abdomen, total lung, > 50% marrow
space)

- Patients who have uncontrolled systemic infections, coagulation disorders, or other
major medical illnesses of the cardiovascular or respiratory systems.

- Patients with any active hepatitis infections.

- Growth factor(s): Must not have received any hematopoetic growth factors within 7 days
of study entry.

- Organ Transplant: Patients may NOT be the recipients of an organ transplant.

- Women who are pregnant and/or lactating.

- Patients who have had major non-biopsy surgery in the last 20 days.

- CNS lesions: A) Patients with CNS parenchymal or meningeal-based lesions that are
present at study entry are NOT eligible due to concerns regarding toxicity
attribution. B) Who have active CNS disease or a history of cranial irradiation are
excluded due to concerns regarding toxicity attribution. Patients with previously
treated leptomeningeal disease or brain metastases without evidence of remaining tumor
by PET, MRI scan, or spinal fluid will be eligible; however such patients currently
taking steroids as prophylaxis against seizures are not eligible.

- Patients with documented allergy to egg products.

- Known history of, or positive test result for human immunodeficiency virus (HIV)
infection.

- Patients with fasting serum triglycerides > 300 and/or with hypertriglyceridemia
requiring medication (but not patients with hypercholesterolemia: patients with
hypercholesterolemia with or without medication are eligible).

- Patients concurrently taking the following drugs are excluded: antioxidants, herbal or
other alternative therapy medications, vitamin supplements (especially vitamins A, C,
and E) other than at standard multivitamin doses, cyclosporine A or analogue;
verapamil; tamoxifen or analogue, ketoconazole, chlorpromazine; RU486; indomethacin;
or sulfinpyrazone, tetracycline, nalidixic acid, nitrofurantoin, phenytoin,
sulfonamides, lithium, and amiodarone. If the patients discontinue usage of the above
drugs, they can be eligible for enrollment into the study (screening visit) one week
or 5-half lives of the drug in question, whichever is the longer, after the
discontinuation. For patients requiring any of these medications, entry is permissible
only with permission from the medical monitor.

- Patients with poorly controlled diabetes mellitus with fasting serum glucose
concentration over 200 mg/dl or a hemoglobin A1C over 7.5%.

- Patients with any known significant cardiac abnormality.

- Patients with uncontrolled hypertension.

- Participation in any other investigational treatment within the 6 weeks prior to
enrollment or concurrent with this study.

- Patients with an identified familial hyperlipidemia disorder.

- Patients with documented allergy to soy products.
We found this trial at
11
sites
500 S Preston St
Louisville, Kentucky
(502) 852-5555
Phone: 502-562-4006
University of Louisville The University of Louisville is a state supported research university located in...
?
mi
from
Louisville, KY
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Phone: 404-778-3255
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
3500 Gaston Avenue
Dallas, Texas 75246
1.800.422.9567
Phone: 214-820-1530
Baylor University Medical Center Baylor University Medical Center in Dallas, TX is ranked nationally in...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Phone: 310-570-1457
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Dallas, Texas 75390
Phone: 214-648-6637
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Gilbert, Arizona 85234
Phone: 480-256-5414
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Greenville, South Carolina 29607
Phone: 864-603-6218
?
mi
from
Greenville, SC
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Phone: 551-996-3129
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Phone: 323-865-0371
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40207
Phone: 502-899-3366
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Westwood, Kansas 66205
Phone: 913-588-8292
?
mi
from
Westwood, KS
Click here to add this to my saved trials